List view / Grid view
With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…
Declining R&D productivity is a key challenge in the pharmaceutical industry today.
In this In-Depth Focus on Screening, we look at clinically-oriented phenotypic screening and explore how 3-D bioprinted tissues can be used as disease-in-a-dish models for drug screening.
In this In-Depth Focus we look at using bioinformatics sequence similarities to optimise repurposing activities; informatics infrastructure in neglected disease research, and machine learning for accelerating drug discovery.
More than 90% of drugs that enter clinical evaluation fail to reach approval because of lack of efficacy or unexpected toxicity. This failure rate is in large part due to the use of overly simplistic in-vitro cell-based assays and animal models with limited predictive value...
In this In-Depth Focus we look at a pragmatic approach to hit validation following biochemical high-throughput screening as well as identification of hits and leads for human African trypanosomiasis.
Understanding the cancer cell phenotype is central to both cancer diagnosis and treatment. Discrete molecular signatures among cancer phenotypes underpin patient stratification, while rapid methods for detailed phenotyping in the clinic (via liquid biopsies and tumour imaging) enable the delivery of personalised, effective precision medicines to the cancer patient...
Issue 4 of Drug Target Review looks at artificial intelligence in drug discovery and features In-Depth Focuses on Screening, Hit to Lead and Informatics.
When important and valuable patents expire, some rejoice and some dismay. Usually, after 20 years of protection, a masterpiece becomes available to all to reproduce, at the loss of the former patent owner...
Flow cytometry continues to evolve at a fast pace and provides neuroscientists with the ability to perform many highly-specialised assays simultaneously. It meets the demands of cutting-edge research in neuroscience that has allowed researchers to isolate particular neural cells from heterogeneous population and catalogue its molecular or physical features...
Image-based high-content screening (HCS) is a high-throughput screening (HTS) technology that combines automated fluorescence microscopy from microtiter plates with digital image analysis. This effectively allows phenotypic screening with sufficient throughput to interrogate large compound libraries...
Drugs exert therapeutically meaningful effects if they bind with appropriate selectively and potency to their respective targets. Although many of the assay techniques employed in early-stage drug discovery provide evidence that a drug is acting upon the target under investigation, this is often indirect and the site of action and…
Physiologically relevant models to evaluate the effects of drug candidates early in the drug discovery and development process are becoming increasingly important to develop. Various 3D cell/tissue models have emerged offering relevant environment for ex vivo assays, but significant progress is required to streamline and automate the end-to-end workflow. Several…
The ever-increasing pressure to turn bench-top discoveries into new therapies has led to the re-purposing of embryonic stem cell lines, originally intended for basic research, for clinical applications...
Flow cytometry has become a widely used technology in life science research. It is also essential for many pharma and biotechnology companies due to its proficiency in identifying biomarkers, developing biopharmaceuticals, and assessing the efficiency of new pharmacological protocols...
